Vaginitis Therapeutics Market Size, Share, & Trends Report

Vaginitis Therapeutics Market Size, Share, & Trends Analysis Report By Product (Anti-fungal, Hormone, Anti-bacterial), By Type (OTC, Prescription), By Region (APAC, MEA, North America), And Segment Forecasts, 2018 - 2025

  • Published Date: Oct, 2018
  • Base Year for Estimate: 2017
  • Report ID: GVR-2-68038-604-2
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 75

Industry Insights

The global vaginitis therapeutics market size was valued at USD 2.20 billion in 2017 and is anticipated to expand at a CAGR of 8.4% during the forecast period. Increasing awareness about women’s health, introduction of new drugs by key companies, and rising demand for improved healthcare infrastructure are some of the major factors driving the market.

U.S. vaginitis therapeutics market

According to the Centers for Disease Control and Prevention (CDC), in 2015, more than 13 of every 100 women were cigarette smokers. The National Institute of Allergy and Infectious Diseases (NIAID) funded scientists to develop the test for yeast infection so as to provide appropriate anti-fungal treatment. In addition, NICHD researchers within the Division of Intramural Population Health research (DIPHR) are using previous and newly collected data to explore various aspects of association between bacterial vaginosis and pregnancy outcome.Rise in research and development activities for accurate diagnosis is projected to boost market growth. Various government and non-government organizations, such as Women Health Organization and European Institute of Women’s Health (EIWH), have undertaken initiatives to increase awareness regarding women’s health. Continuous research and development activities by various companies and changing lifestyle pattern of women across the globe, such as smoking and alcohol consumption, are the key factors driving the market growth.

Product Insights

On the basis of product, vaginitis therapeutics market is segmented into anti-fungal, anti-bacterial, and hormone. Anti-bacterial segment held the largest market share owing to rising cases of bacterial vaginosis. Anti-bacterial market was valued at USD 900 million in 2017, in terms of revenue.It was reported that around 21 million women were suffering from this problem. Drugs used for the treatment of bacterial vaginosis metronidazole, clindamycin, and tinidazole.

While hormonal treatment segment is expected to witness the fastest growth over the forecast period. Most of the hormonal treatments are available only through prescription. The presence of strong pipeline drugs is expected to support the segment’s fastest growth over the forecast period.

Type Insights

On the basis of type, market is categorized into Over-The-Counter (OTC) and prescription (Rx). Among these, prescribed type accounts for the largest market share owing to higher efficacy and safety for severe and recurring vaginitis. OTC is expected to expand at a CAGR of 8.7% during the estimated period due to the presence of wide range of OTC drugs, such as vaginal creams, gels, and others. Furthermore, for non-prescribed drugs, FDA has approved treatment options for mild vaginitis for external use. These include tioconazole miconazole, clotrimazole, and butoconazole in the form of cream, tablets, and suppositories.

Regional Insights

North America led the global market in 2017 and was valued at USD 861.2 million. Established healthcare infrastructure in this region along with high prevalence of disease and presence of key manufacturers is a major factor responsible for its largest share. Other factors, such as favorable government initiatives and growing target population are also propelling the market growth.

Global vaginitis therapeutics market

Asia Pacific is estimated to witness the fastest growth with CAGR of around 9.6% during the forecast period. This is attributed to high unmet clinical needs, rising disposable income increased awareness about early diagnosis, and availability of effective drugs in emerging countries, such as India and China.

Vaginitis Therapeutics Market Share Insights

Key companies in this industry are Pfizer, Inc.; Merck & Co.; Novartis AG; Bayer AG; Lupin Pharmaceuticals, Inc.; Symbiomix Therapeutics, Inc.; and Mission Pharmacal Company.

Most of these companies are adopting strategies, such as collaborations, new drug development, M&A, business expansion in emerging regions. For instance, in October 2017, Lupin Pharmaceuticals acquired Symbiomix Therapeutics to increase its product portfolio. In October 2017, Pfizer Inc. announced the review of strategic alternative for spin off its Consumer Healthcare Business as a strategic initiative.

Report Scope

Attribute

Details

Base year for estimation

2017

Actual estimates/Historical data

2014 - 2016

Forecast period

2018 - 2025

Market representation

Revenue in USD Million & CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, and MEA

Country scope

U.S., Canada, U.K., Germany, Japan, China, Brazil, Mexico, and South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope(equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global vaginitis therapeutics market report on the basis of product, type, and region:

  • Product Outlook (Revenue, USD Million, 2014 - 2025)

    • Anti-fungal

    • Anti-bacterial

    • Hormone

  • Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Over-The-Counter (OTC)

    • Prescription (Rx)

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

      • Mexico

    • MEA

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified